4D Molecular Therapeutics
Engineers virus-based gene therapies for eye and lung diseases, led by a late-stage retinal candidate.
$14.67
After-hours close+0.01 (+0.07%)
At close$14.66(−1.68%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 111.71%Insiders 1.77%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 52.28M · Float 39.01M · 74.6% free float
Institutions13F, as of Jun 30, 2026
166 holders · 58.40M shares · 35 new positions · 96 increased · 38 reduced · 24 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Jupiter Topco LLC | 5.75M | 10.99% | +5.75Mnew | Aug 14, 2026 |
| Ra Capital Management, L.P. | 5.05M | 9.66% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 4.55M | 8.70% | +400.8K | Aug 7, 2026 |
| Goldman Sachs Group Inc | 4.26M | 8.15% | +53.2K | Aug 14, 2026 |
| Novo Holdings A/S | 3.25M | 6.22% | −401.6K | Aug 14, 2026 |
| State Street Corp | 2.91M | 5.57% | +203.2K | Aug 7, 2026 |
| BVF Inc/IL | 2.88M | 5.51% | 0 | Aug 14, 2026 |
| T. Rowe Price Investment Management, Inc. | 2.51M | 4.81% | +2.51Mnew | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Janus Henderson Group PLC | 10.30% | 5.25M | 13G | Apr 7, 2026 ↗ |
| RA Capital Management, L.P. | 9.90% | 5.11M | 13G | May 15, 2026 ↗ |
| The Goldman Sachs Group, Inc. | 7.50% | 4.29M | 13G | Feb 9, 2026 ↗ |
| Biotechnology Value Fund L P | 7.30% | 3.91M | 13G | May 15, 2026 ↗ |
| BlackRock, Inc. | 6.60% | 3.06M | 13G | Oct 17, 2025 ↗ |
| Novo Holdings A/S | 6.40% | 3.65M | 13G | Feb 17, 2026 ↗ |
| State Street Corporation | 5.30% | 2.71M | 13G | May 12, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| David Kirn | director, officer: See Remarks | 825.8K | 1.58% | Aug 21, 2026 |
| Ashoo Gupta | officer: VP, Finance and Controller | 46.9K | 0.09% | Mar 24, 2026 |
| Charles Theuer | director | 41.7K | 0.08% | Dec 16, 2025 |
| Scott Bizily | officer: Chief Legal Officer | 8.6K | 0.02% | Aug 17, 2026 |
2 ten-percent owners hold 8.81M shares by Form 4, outside the officers-and-directors figure above · 7 people have not refiled in the last 18 months (1.11M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 19, 2026 | David Kirndirector, officer: See Remarks | Sale · 2 lots | 69,076 | $15.75 | 825,819 |
| Aug 17, 2026 | Scott Bizilyofficer: Chief Legal Officer | Sale | 1,635 | $12.20 | 8,617 |
| Aug 13, 2026 | Scott Bizilyofficer: Chief Legal Officer | Sale | 1,635 | $12.00 | 8,617 |
| Aug 4, 2026 | David Kirndirector, officer: See Remarks | Sale | 26,842 | $10.23 | 844,895 |
| Aug 3, 2026 | David Kirndirector, officer: See Remarks | Sale | 12,415 | $10.05 | 871,737 |
| Jul 10, 2026 | David Kirndirector, officer: See Remarks | Sale · 2 lots | 15,725 | $12.03 | 884,152 |
| Jul 9, 2026 | David Kirndirector, officer: See Remarks | Sale | 42,608 | $12.87 | 899,877 |
| Jun 30, 2026 | Scott Bizilyofficer: Chief Legal Officer | Sale | 6,566 | $14.00 | 8,617 |
| Jun 23, 2026 | Scott Bizilyofficer: Chief Legal Officer | Sale | 9,810 | $12.00 | 8,617 |
| Jun 22, 2026 | David Kirndirector, officer: See Remarks | Sale | 114,746 | $10.47 | 942,485 |
CongressHouse and Senate disclosures
Not reported.